August 10, 2023 Team Rxtrospect U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma August 10, 2023 Team Rxtrospect SCHEDULE A CALL Team Rxtrospect